Apotex manufacturing, R&D project in Florida comes with 150 jobs

Canadian generics producer Apotex has started construction on a manufacturing facility to make pain meds, as well as a packaging facility and a new R&D center in Miramar, Florida.

Canadian generics producer Apotex has embarked on a $184 million project in South Florida that includes a new manufacturing plant and 150 new jobs.

The drugmaker announced Wednesday that is has started construction on a manufacturing facility to make pain meds, as well as a packaging facility and a new R&D center in Miramar, Florida. The project is slated to be complete in 2019.

Apotex, which now has its U.S. headquarters in Weston, Florida, moved to the area with its 2012 acquisition of transdermal patch maker Avena.

Conference

The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

It said it decided on South Florida for its new facility because of its proximity to Latin America and “to capture the benefits of Broward County's business environment.” Authorities are providing an unspecified amount of incentives. But it also is expanding in the U.S. because of the laws regulating controlled substances.

“In addition, due to U.S. regulations, we are only permitted to manufacture controlled substances in the U.S. when serving this market, so expansion in Canada was not feasible,” CEO Jeremy B. Desai, said in a statement.

The company told Bloomberg the facility will make pain medications and allow it to double production of transdermal patches.

Suggested Articles

Chinese biotech CMBG hopes to get a cell manufacturing facility built in nine months and more manufacturing news of note.

Kite has been buying the viral vector starting material for its CAR-T treatment Yescarta from contractors but says it is time to produce its own.  

Indoco Remedies is not just getting the once over by the FDA but the twice-over as inspectors work through its plants and citations rain down.